EDUCATION EXHIBIT - Virtual Journal Club/Continuing Medical Education

Scintigraphic Manifestations of Thyrotoxicosis

Published Online:https://doi.org/10.1148/rg.234025716

The term thyrotoxicosis refers to the clinical syndrome of increased systemic metabolism that results when the serum concentrations of free thyroxine, free triiodothyronine, or both are elevated. The term hyperthyroidism refers to overactivity of the thyroid gland with a resultant increase in thyroid hormone synthesis and release into the systemic circulation. These terms are not interchangeable, since thyrotoxicosis can develop in thyroid conditions that are not associated with increased thyroid function, such as thyroiditis, or in so-called factitious hyperthyroidism. The clinical signs and symptoms of thyrotoxicosis are virtually identical regardless of the cause. However, in a given patient, every attempt should be made to determine the exact cause of the thyrotoxicosis, as this in turn determines the prognosis and treatment. Since thyroid scintigraphy demonstrates the functional state of the thyroid gland, it should be used, in conjunction with determination of radioactive iodine uptake, as the imaging modality of choice for diagnosis of thyrotoxicosis. Although the scintigraphic features of several of the thyroid disorders that cause thyrotoxicosis may overlap, their recognition helps narrow the differential diagnosis, thereby guiding the referring physician in the work-up and management of this disorder.

© RSNA, 2003

References

  • 1 Ridgway EC. Clinical evaluation of solitary thyroid nodules. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s the thyroid. 8th ed. Philadelphia, Pa: Lippincott-Raven, 2000; 949-956. Google Scholar
  • 2 Eisenberg B, Arrington ER, Haygood TM, Kelsey CA. Thyroid scintigraphic patterns, radioactive iodine uptake, and Nuclear Regulatory Commission guidelines for radioiodine use. In: Eisenberg B, eds. Imaging of thyroid and parathyroid glands: a practical guide. New York, NY: Churchill Livingstone, 1991; 51-57. Google Scholar
  • 3 Zakarija M, McKenzie J, Banoviac K. Clinical significance of thyroid-stimulating antibody in Graves’ disease. Ann Intern Med 1980; 93:28-32. Crossref, MedlineGoogle Scholar
  • 4 Harbert JC. Radioiodine therapy of hyperthyroidism. Harbert JC, Eckelman WC, Neumann RD, et al. Nuclear medicine: diagnosis and therapy. New York, NY: Thieme Medical, 1996; 959-973. Google Scholar
  • 5 Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves’ disease. J Clin Endocrinol Metab 1990; 70:1518-1524. Crossref, MedlineGoogle Scholar
  • 6 Hedley AJ, Young RE, Jones SJ, et al. Antithyroid drugs in the treatment of hyperthyroidism of Graves’ disease: long-term follow-up of 434 patients. Clin Endocrinol 1989; 31:209-218. Crossref, MedlineGoogle Scholar
  • 7 Charkes ND. Graves’ disease with functioning nodules (Marine-Lenhart syndrome). J Nucl Med 1972; 13:885-892. MedlineGoogle Scholar
  • 8 Davies TF, Larsen PR. Thyrotoxicosis. In: Larsen PR, Kronenberg HM, Melmed S, Polansky KS, eds. Williams textbook of endocrinology. 10th ed. Philadelphia, Pa: Saunders, 2003; 374-455. Google Scholar
  • 9 VanSande J, Lamy F, Lecocq R, et al. Pathogenesis of autonomous thyroid nodules: in vitro study of iodine and adenosine 3′,5′-monophosphate metabolism. J Clin Endocrinol Metab 1988; 66:570-589. Crossref, MedlineGoogle Scholar
  • 10 Corvilain B, Dumont J, Vassart G. Toxic adenoma and toxic multinodular goiter. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s the thyroid. 8th ed. Philadelphia, Pa: Lippincott-Raven, 2000; 564-572. Google Scholar
  • 11 Goldstein R, Hart IR. Follow-up of solitary autonomous thyroid nodules treated with 131I. N Engl J Med 1983; 309:1473-1476. Crossref, MedlineGoogle Scholar
  • 12 Clerc J, Dagousset F, Izembart M, et al. Radioiodine therapy of the autonomous thyroid nodule in patients with and without visible extranodular activity. J Nucl Med 1995; 36:217-223. MedlineGoogle Scholar
  • 13 Peter HJ, Gerber H, Studer H, et al. Pathogenesis of heterogeneity in human multinodular goiter. J Clin Invest 1985; 76:1992-2002. Crossref, MedlineGoogle Scholar
  • 14 Van Soestbergen MJM, Van der Vijver JCM, Graafland AD. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves’ disease. J Endocrinol Invest 1992; 15:797-800. Crossref, MedlineGoogle Scholar
  • 15 Thomas CG, Jr, Croom RD. Current management of the patient with autonomously functioning nodular goiter. Surg Clin North Am 1987; 67:315-328. Crossref, MedlineGoogle Scholar
  • 16 Volpe R. Subacute thyroiditis. In: Burrow GN, Oppenheimer JH, Volpe R, eds. Thyroid function and disease. Philadelphia, Pa: Saunders, 1989; 179-187. Google Scholar
  • 17 Volpe R. The management of subacute (de Quervain’s) thyroiditis. Thyroid 1993; 3:253-257. Crossref, MedlineGoogle Scholar
  • 18 Hamburger JI. The various presentations of thyroiditis: diagnostic considerations. Ann Intern Med 1986; 104:219-224. Crossref, MedlineGoogle Scholar
  • 19 Nikolai TF, Brosseau J, Kettrick MA, et al. Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med 1980; 140:478-482. Crossref, MedlineGoogle Scholar
  • 20 Nikolai TF, Combs GJ, McKenzie AK, et al. Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med 1982; 142:2281-2283. Crossref, MedlineGoogle Scholar
  • 21 Martins ML, Lima N, Knobel M, et al. Natural course of iodine-induced thyrotoxicosis (Jod Basedow) in endemic goiter area: a 5 year follow-up. J Endocrinol Invest 1989; 12:239-244. Crossref, MedlineGoogle Scholar
  • 22 Vagenalsis AG, Wang CA, Burger A, et al. Iodine-induced thyrotoxicosis in Boston. N Engl J Med 1972; 287:523-527. Crossref, MedlineGoogle Scholar
  • 23 Seminara MD, Daniels GH. Amiodarone and the thyroid. Endocr Pract 1998; 4:48-54. Crossref, MedlineGoogle Scholar
  • 24 Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases. Clin Endocrinol 1987; 26:227-237. Crossref, MedlineGoogle Scholar
  • 25 Reichert LJ, deRooy HA. Treatment of amiodarone induced hyperthyroidism with potassium perchlorate and methimazole during amiodarone treatment. BMJ 1989; 298:1547-1548. Crossref, MedlineGoogle Scholar
  • 26 Brousolle C, Ducotett X, Martin C, et al. Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis: comparison of two groups of patients with apparently normal thyroid glands. J Endocrinol Invest 1989; 12:37-42. Crossref, MedlineGoogle Scholar
  • 27 Eliason BC, Doenier JA, Nuhlicek DN. Desiccated thyroid in a nutritional supplement. J Fam Pract 1994; 38:287-288. MedlineGoogle Scholar
  • 28 Hedberg CW, Fishbein DB, Janssen RS, et al. An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med 1987; 316:993-998. Crossref, MedlineGoogle Scholar
  • 29 Cohen JH, Inbar SH, Braverman LE. Thyrotoxicosis due to ingestion of excess thyroid hormone. Endocr Rev 1989; 10:113-124. Crossref, MedlineGoogle Scholar
  • 30 Steffenson FH, Aunsholt NA. Hyperthyroidism associated with metastatic thyroid carcinoma. Clin Endocrinol 1994; 41:685-687. Crossref, MedlineGoogle Scholar
  • 31 McDougall IR. Hyperthyroidism. Thyroid disease in clinical practice. New York, NY: Oxford University Press, 1992; 82-162. CrossrefGoogle Scholar
  • 32 Desai RK, Norman RJ, Jialal I, Joubert SM. Spectrum of thyroid function abnormalities in gestational trophoblastic neoplasia. Clin Endocrinol 1988; 29:583-592. Crossref, MedlineGoogle Scholar
  • 33 Smallridge RC, Smith CE. Hyperthyroidism due to thyrotropin-secreting pituitary tumors. Arch Intern Med 1983; 143:503-507. Crossref, MedlineGoogle Scholar
  • 34 Intenzo CM, Capuzzi DM, Jabbour S, Kim SM, dePapp AE. Scintigraphic features of autoimmune thyroiditis. RadioGraphics 2001; 21:957-964. LinkGoogle Scholar

Article History

Published in print: July 2003